Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib + AK105 vs chemotherapy in second-line advanced gastric or gastroesophageal junction adenocarcinoma
CTR20200753Phase 3Terminated
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- May 2020
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of catequentinib, penpulimab in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, sponsored by Chia Tai-Tianqing Pharmaceutical Group. Started May 2020; status: terminated.
02
Drugs
catequentinibpenpulimab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on CTR20200753.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20200753.